JP2015199700A - Neutral fat absorption-suppressing composition - Google Patents
Neutral fat absorption-suppressing composition Download PDFInfo
- Publication number
- JP2015199700A JP2015199700A JP2015037298A JP2015037298A JP2015199700A JP 2015199700 A JP2015199700 A JP 2015199700A JP 2015037298 A JP2015037298 A JP 2015037298A JP 2015037298 A JP2015037298 A JP 2015037298A JP 2015199700 A JP2015199700 A JP 2015199700A
- Authority
- JP
- Japan
- Prior art keywords
- polydextrose
- mass
- composition
- mixture
- neutral fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 135
- 230000007935 neutral effect Effects 0.000 title claims abstract description 23
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 208
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 104
- 239000001259 polydextrose Substances 0.000 claims abstract description 104
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 104
- 229940035035 polydextrose Drugs 0.000 claims abstract description 104
- 239000000693 micelle Substances 0.000 claims abstract description 56
- 239000003613 bile acid Substances 0.000 claims abstract description 51
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 45
- 239000002245 particle Substances 0.000 claims abstract description 33
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 31
- 239000007864 aqueous solution Substances 0.000 claims abstract description 30
- 238000010521 absorption reaction Methods 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000000178 monomer Substances 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000001629 suppression Effects 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 abstract description 11
- 230000009467 reduction Effects 0.000 abstract description 2
- 239000003925 fat Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 239000007788 liquid Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 11
- 238000010951 particle size reduction Methods 0.000 description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
- 239000000600 sorbitol Substances 0.000 description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 238000000265 homogenisation Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000004375 Dextrin Substances 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 6
- 239000004367 Lipase Substances 0.000 description 6
- 102000004882 Lipase Human genes 0.000 description 6
- 108090001060 Lipase Proteins 0.000 description 6
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 6
- 235000019425 dextrin Nutrition 0.000 description 6
- 229940040461 lipase Drugs 0.000 description 6
- 235000019421 lipase Nutrition 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000003858 bile acid conjugate Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- -1 glucose Chemical class 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940127470 Lipase Inhibitors Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 210000001819 pancreatic juice Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000001162 steatorrhea Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- DKPMWHFRUGMUKF-UHFFFAOYSA-N (3alpha,5alpha,6alpha,7alpha)-3,6,7-Trihydroxycholan-24-oic acid Natural products OC1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DKPMWHFRUGMUKF-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- JOYGXTIHTHBSOA-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-thiophen-2-ylprop-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C=CC1=CC=CS1 JOYGXTIHTHBSOA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- UPWGQKDVAURUGE-KTKRTIGZSA-N 2-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO UPWGQKDVAURUGE-KTKRTIGZSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102100026367 Pancreatic alpha-amylase Human genes 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical group C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000020958 lipid digestion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、中性脂肪吸収抑制組成物、特に胆汁酸ミセルの粒径低下抑制により中性脂肪の体内吸収を抑制する中性脂肪吸収抑制組成物に関する。 The present invention relates to a neutral fat absorption inhibitory composition, and more particularly to a neutral fat absorption inhibitory composition that suppresses in vivo absorption of neutral fat by suppressing particle size reduction of bile acid micelles.
従来の中性脂肪吸収抑制技術は、リパーゼ阻害作用によるものが主であった。リパーゼは、消化管内に分泌される膵液に含まれており、トリグリセリドを吸収されやすい分子である脂肪酸とモノグリセリドに分解する重要な消化酵素である。このリパーゼの活性を阻害することでトリグリセリドの消化を阻害し、吸収を抑制することができる。例えば、リパーゼ阻害を作用機序とした脂肪吸収阻害を示す薬剤としてオルリスタットがある。 Conventional neutral fat absorption suppression technology has been mainly based on lipase inhibition. Lipase is contained in the pancreatic juice secreted into the digestive tract, and is an important digestive enzyme that breaks down triglycerides into fatty acids and monoglycerides that are easily absorbed. By inhibiting the activity of this lipase, digestion of triglycerides can be inhibited and absorption can be suppressed. For example, orlistat is a drug that shows fat absorption inhibition using lipase inhibition as a mechanism of action.
しかしながら、リパーゼ阻害薬は副作用として脂肪便が出ることが課題となっている。リパーゼが阻害された場合、食事から摂取した脂肪が消化されずにそのまま便として排泄されるため、放屁などの際に肛門から油が出てしまうなどQOLが著しく低下することが問題となっている。 However, a problem with lipase inhibitors is that fatty stool appears as a side effect. When lipase is inhibited, the fat taken from the meal is excreted as stool without being digested, so that there is a problem that the QOL is remarkably lowered, such as oil coming out from the anus during the release. .
胆汁酸ミセルの粒径制御による脂肪吸収抑制は、リパーゼのはたらきを阻害せず、脂肪は脂肪酸とモノグリセリドに分解されるため、脂肪便のように未消化の油が排泄される副作用はない。一方で、胆汁酸ミセル粒径を制御し、その粒径の低下を抑制することで、胆汁酸ミセルを介した脂肪の吸収を遅延させることができる。すなわち胆汁酸ミセルの粒径を制御し、その低下を抑制することによって、リパーゼ阻害薬の副作用である脂肪便を抑制し、脂肪吸収を抑制することができる。 The suppression of fat absorption by controlling the particle size of bile acid micelles does not inhibit the function of lipase, and fat is decomposed into fatty acids and monoglycerides, so there is no side effect of excreting undigested oil like fatty stool. On the other hand, the absorption of fat via bile acid micelles can be delayed by controlling the bile acid micelle particle size and suppressing the decrease in the particle size. That is, by controlling the particle size of bile acid micelles and suppressing the decrease thereof, fat stool, which is a side effect of lipase inhibitors, can be suppressed, and fat absorption can be suppressed.
ミセル(micelle)とは、界面活性剤などの両親媒性分子の極性親水性部分が外側に伸び、無極性疎水性部分が内側に伸びている状態で複数の該分子が集まって形成された球状構造をいう。例えば、水と油を界面活性剤と共に混合すると、界面活性剤の親油性部分が油と共に内部に、親水性部分が水との界面に向くように配向し、ミセル構造が形成される。ミセルのうち、胆汁酸ミセルは、胆汁酸の存在下で形成されるミセルであり、通常、生体内において、胆汁酸、脂肪酸及びモノグリセリドなどにより形成されている。この胆汁酸ミセルは、例えば生体内において、以下のようにして脂質の消化吸収過程に関与することが知られている。 A micelle is a sphere formed by collecting a plurality of such molecules in a state where the polar hydrophilic portion of an amphiphilic molecule such as a surfactant extends outward and the nonpolar hydrophobic portion extends inward. Refers to the structure. For example, when water and oil are mixed together with a surfactant, the lipophilic part of the surfactant is oriented with the oil inside and the hydrophilic part is oriented toward the interface with water to form a micelle structure. Among micelles, bile acid micelles are micelles formed in the presence of bile acids, and are usually formed in vivo by bile acids, fatty acids, monoglycerides, and the like. These bile acid micelles are known to participate in the lipid digestion and absorption process as follows, for example, in vivo.
食品に含まれる脂肪の多くは、化学的に安定した中性脂肪、つまりトリグリセリドである。食事として体内に摂取された中性脂肪は、以下のように消化吸収されることが知られている。まず、中性脂肪は、十二指腸で胆汁により乳化される。次に膵液中に含まれる膵リパーゼの働きで、モノグリセリドと脂肪酸に分解される。モノグリセリドと脂肪酸は、腸内に分泌された胆汁酸と接することにより胆汁酸ミセルを形成し、この胆汁酸ミセルを介して吸収される。胆汁酸ミセルは、その粒径が小さいほど、吸収されやすいことが知られている。したがって、胆汁酸ミセルの粒径を制御し、粒径の低下を抑制する組成物は、脂肪吸収を抑制できると考えられる。 Many of the fats in food are chemically stable neutral fats, or triglycerides. It is known that neutral fat taken into the body as a meal is digested and absorbed as follows. First, neutral fat is emulsified with bile in the duodenum. Next, it is decomposed into monoglycerides and fatty acids by the action of pancreatic lipase contained in the pancreatic juice. Monoglycerides and fatty acids form bile acid micelles by contact with bile acids secreted into the intestine, and are absorbed through the bile acid micelles. It is known that bile acid micelles are more easily absorbed as the particle size is smaller. Therefore, it is considered that a composition that controls the particle size of bile acid micelles and suppresses the decrease in particle size can suppress fat absorption.
これまでに、水溶性食物繊維の一種である難消化性デキストリンが、胆汁酸ミセルの粒径低下を抑制し、脂肪吸収を抑制することが報告されている(非特許文献1)。 So far, it has been reported that indigestible dextrin, which is a kind of water-soluble dietary fiber, suppresses the decrease in the particle size of bile acid micelles and suppresses fat absorption (Non-patent Document 1).
しかしながら、難消化性デキストリンによる胆汁酸ミセルの粒径低下抑制作用は十分なものとは言い難い。
本発明の課題は、胆汁酸ミセルの粒径低下抑制について、難消化性デキストリンよりも更に高い作用を有し、脂肪の吸収を遅延することにより、体内への中性脂肪の吸収を効果的に抑制しうる中性脂肪吸収抑制組成物を提供することにある。
However, it is difficult to say that the effect of suppressing the particle size reduction of bile acid micelles by indigestible dextrin is sufficient.
The object of the present invention is to suppress the decrease in the particle size of bile acid micelles, which has a higher action than indigestible dextrin, and effectively absorbs neutral fat into the body by delaying fat absorption. An object of the present invention is to provide a neutral fat absorption suppressing composition that can be suppressed.
本発明は、有効成分としてポリデキストロースを含む、中性脂肪吸収抑制組成物を提供するものである。 The present invention provides a neutral fat absorption inhibiting composition containing polydextrose as an active ingredient.
本発明の組成物によれば、胆汁酸ミセルの粒径低下を効果的に抑制させることができ、脂肪の吸収を遅延することにより、体内への中性脂肪の吸収抑制に有効でありうる。 According to the composition of the present invention, the particle size reduction of bile acid micelles can be effectively suppressed, and it can be effective in suppressing the absorption of neutral fat into the body by delaying the absorption of fat.
以下、本発明の中性脂肪吸収抑制組成物について、その好ましい実施形態に基づき説明する。本発明は、胆汁酸ミセルの粒径低下抑制により、脂肪吸収抑制を図るものであり、胆汁酸ミセルの粒径低下抑制組成物としても用いられる。また、本発明は、胆汁酸ミセルの粒径低下抑制により、脂質の体外への排出促進を図るものである。以下、これらの組成物を単に本発明の組成物ともいう。 Hereinafter, the neutral fat absorption inhibiting composition of the present invention will be described based on preferred embodiments thereof. The present invention is intended to suppress fat absorption by suppressing particle size reduction of bile acid micelles, and is also used as a composition for suppressing particle size reduction of bile acid micelles. In addition, the present invention aims to promote the excretion of lipids outside the body by suppressing the decrease in the particle size of bile acid micelles. Hereinafter, these compositions are also simply referred to as the composition of the present invention.
本発明の組成物は、ポリデキストロースを含むことにより、胆汁酸ミセルの粒径低下を効果的に抑制する。 The composition of this invention suppresses the particle size fall of a bile acid micelle effectively by containing polydextrose.
ポリデキストロースは、グルコースがα-又はβ-型の1-2、1-3、1-4、又は1-6結合で分岐状に多数重合した構造を有する、水溶性かつ難消化性の多糖類であり、その一部は食物繊維としてはたらく。ポリデキストロースは、例えば、グルコース、ソルビトール、クエン酸を凡そ89:10:1、またはグルコース、ソルビトール、リン酸を凡そ90:10:0.1の質量比で混合後、高温条件下で重合させることによって製造される。また、ポリデキストロース量は米国のFederal Chemicals Codexや平成18年7月21日食安発第0721001号の別紙記載の方法によって測定される。 Polydextrose is a water-soluble and indigestible polysaccharide that has a structure in which glucose is polymerized in a branched manner with α- or β-type 1-2, 1-3, 1-4, or 1-6 bonds. And some of them work as dietary fiber. Polydextrose is produced, for example, by mixing glucose, sorbitol, and citric acid at a mass ratio of about 89: 10: 1, or glucose, sorbitol, and phosphoric acid at a mass ratio of about 90: 10: 0.1, and then polymerizing them under high temperature conditions. Is done. The amount of polydextrose is measured by the methods described in the US Federal Chemicals Codex and the separate sheet of July 21, 2006, from Shokuyasu No. 0721001.
本発明においては、ポリデキストロース源として、ポリデキストロースと、その原料となる重合性単量体の1種又は2種以上を不純物として含む混合物(以下、ポリデキストロース混合物ともいう)を用いてもよいし、不純物を除去したポリデキストロースのみを用いてもよい。このポリデキストロース混合物に含まれる重合性単量体としてはポリデキストロース製造の原料である前述のグルコースや、ソルビトールを挙げることができる。つまり、前記のポリデキストロース混合物は、例えばポリデキストロース、グルコース及びソルビトールからなるものであってもよい。ポリデキストロース混合物は、通常固形状である。ポリデキストロース混合物は、水分量が例えば5質量%以下、特に4質量%以下であることが好ましい。 In the present invention, as a polydextrose source, a mixture containing polydextrose and one or more polymerizable monomers as raw materials as impurities (hereinafter also referred to as a polydextrose mixture) may be used. Alternatively, only polydextrose from which impurities have been removed may be used. Examples of the polymerizable monomer contained in the polydextrose mixture include the aforementioned glucose, which is a raw material for producing polydextrose, and sorbitol. That is, the polydextrose mixture may be composed of, for example, polydextrose, glucose and sorbitol. The polydextrose mixture is usually solid. The polydextrose mixture preferably has a water content of, for example, 5% by mass or less, particularly 4% by mass or less.
ポリデキストロース混合物中のグルコース及びソルビトールの合計量は、10質量%以下であることが好ましく、6質量%以下であることがより好ましい。ポリデキストロース混合物中のグルコース及びソルビトールの合計量は少なければ少ないほどよいが、1質量%以上であると、ポリデキストロースの製造コストの観点から好ましい。グルコース及びソルビトールの含有量は、既知の各種定量法により測定できる。 The total amount of glucose and sorbitol in the polydextrose mixture is preferably 10% by mass or less, and more preferably 6% by mass or less. The smaller the total amount of glucose and sorbitol in the polydextrose mixture, the better. However, it is preferably 1% by mass or more from the viewpoint of the production cost of polydextrose. The contents of glucose and sorbitol can be measured by various known quantitative methods.
また、ポリデキストロース混合物は、該混合物中における後述する(A)食物繊維と、(B)グルコース及びソルビトールの合計量の比(A)/(B)が、8.3以上、特に12.5以上であることが好ましい。 Further, in the polydextrose mixture, the ratio (A) / (B) of the total amount of (A) dietary fiber and (B) glucose and sorbitol described later in the mixture is 8.3 or more, particularly 12.5 or more. preferable.
ポリデキストロース及びポリデキストロース混合物は、食物繊維を含有する。食物繊維とは、食物に含まれている成分のうち、ヒトの消化酵素で消化されない難消化性成分である。ポリデキストロースは、上述したように、グルコース等の単糖が重合した多糖類であり、このうち、ある程度以上の分子量のものが、食物繊維に該当すると考えられる。 Polydextrose and polydextrose mixtures contain dietary fiber. Dietary fiber is an indigestible component that is not digested by human digestive enzymes among the components contained in food. As described above, polydextrose is a polysaccharide obtained by polymerizing monosaccharides such as glucose, and among these, those having a molecular weight of a certain level or more are considered to be dietary fibers.
本発明において、前述したポリデキストロース混合物を用いる場合、該ポリデキストロース混合物における食物繊維量が50質量%以上であることが、原料由来の不純物による甘味や雑味を低減でき、またミセルの粒径低下を効果的に抑制する観点から好ましい。前記混合物中の食物繊維量は、60質量%以上であることが更に好ましく、65質量%以上であることが更に一層好ましく、70質量%以上であることが特に好ましい。また、前記混合物中の食物繊維量は、高ければ高いほど好ましいが、例えば95質量%以下であると、製造コストの点で有利である。 In the present invention, when the polydextrose mixture described above is used, the amount of dietary fiber in the polydextrose mixture is 50% by mass or more, so that sweetness and miscellaneous taste due to impurities derived from the raw material can be reduced, and the micelle particle size is reduced. From the viewpoint of effectively suppressing the above. The amount of dietary fiber in the mixture is more preferably 60% by mass or more, still more preferably 65% by mass or more, and particularly preferably 70% by mass or more. Moreover, although the amount of dietary fiber in the said mixture is so preferable that it is high, it is advantageous at the point of manufacturing cost that it is 95 mass% or less, for example.
本発明において、ポリデキストロース混合物に含まれる食物繊維量を前記の範囲とするためには、前述した方法でポリデキストロースを製造した後、該重合により得られた反応物を公知の方法で精製等すればよい。 In the present invention, in order to keep the amount of dietary fiber contained in the polydextrose mixture within the above range, after producing polydextrose by the above-described method, the reaction product obtained by the polymerization may be purified by a known method. That's fine.
なお、ポリデキストロース混合物中に含まれる食物繊維量は酵素-HPLC法(「栄養表示基準における栄養成分等の分析方法等について」、平成11年4月26日衛新第13号、8食物繊維)に準じ、測定する。具体的には以下のように行う。 In addition, the amount of dietary fiber contained in the polydextrose mixture is the enzyme-HPLC method ("Analytical methods for nutritional components, etc. in nutrition labeling standards", April 26, 1999, Eishin No. 13, 8 dietary fiber) Measure according to. Specifically, it is performed as follows.
まず、サンプル500mgを精密に測り、0.08mol/lリン酸緩衝液(pH6.0±0.5)50mlを加える。これに熱安定性α-アミラーゼ(Sigma社:EC3.2.1.1 Bacillus licheniformis由来)溶液0.1mlを加え、沸騰水中に入れ、10分ごとに撹拌しながら30分間放置する。冷却後、0.275mol/l水酸化ナトリウム溶液を加えてpHを7.5±0.1に調整する。プロテアーゼ(Sigma社:EC3.4.21.62 Bacillus licheniformis由来)溶液0.1mlを加えて、60±2℃の水浴中で振とうしながら30分間反応させる。冷却後、0.325mol/l塩酸を加え、pHを4.3±0.3に調整する。アミログルコシダーゼ(Sigma社:EC3.2.13 Aspergillus niger由来)溶液0.1mlを加え、60±2℃の水浴中で振とうしながら30分間反応させる。以上の酵素処理終了後、直ちに沸騰水浴中で10分間加熱した後、冷却し、50ml遠沈菅に分注し、10分間遠心分離した後、上清を回収する。残渣に純水10mlを加えよく攪拌し再度遠心分離して上清を回収し、これらを酵素処理液とする。酵素処理液全量をイオン交換樹脂(OH型:H型=1:1)50mlを充填したカラム(ガラス管20mm×300mm)に通液速度80ml/hrで通液し、さらに純水を通して流出液の全量を約250mlとする。この溶液をロータリー・エバポレーターで濃縮し、全量を純水で50mlとする。孔径0.45μmのメンブレンフィルターでろ過し、検液とする。またグリセリンを純水で5mg/ml、10mg/ml、15mg/mlに調製し標準溶液とする。 First, 500 mg of a sample is accurately measured, and 50 ml of 0.08 mol / l phosphate buffer (pH 6.0 ± 0.5) is added. To this, 0.1 ml of a thermostable α-amylase (Sigma: EC 3.2.1.1 Bacillus icheniformis derived) solution is added, placed in boiling water, and allowed to stand for 30 minutes with stirring every 10 minutes. After cooling, 0.275 mol / l sodium hydroxide solution is added to adjust the pH to 7.5 ± 0.1. Add 0.1 ml of protease (from Sigma: EC 3.4.21.62 Bacillus icheniformis ) solution and react for 30 minutes while shaking in a water bath at 60 ± 2 ° C. After cooling, 0.325 mol / l hydrochloric acid is added to adjust the pH to 4.3 ± 0.3. Add 0.1 ml of amyloglucosidase (Sigma: EC 3.2.13 Aspergillus niger ) solution, and allow to react for 30 minutes while shaking in a 60 ± 2 ° C. water bath. Immediately after completion of the above enzyme treatment, it is heated in a boiling water bath for 10 minutes, then cooled, dispensed into 50 ml centrifuges, centrifuged for 10 minutes, and the supernatant is recovered. Add 10 ml of pure water to the residue, stir well, centrifuge again to collect the supernatant, and use these as the enzyme treatment solution. The total amount of the enzyme treatment solution was passed through a column (glass tube 20 mm × 300 mm) packed with 50 ml of ion exchange resin (OH type: H type = 1: 1) at a flow rate of 80 ml / hr, and the effluent was further passed through pure water The total volume is about 250 ml. This solution is concentrated by a rotary evaporator, and the whole volume is made up to 50 ml with pure water. Filter through a membrane filter with a pore size of 0.45 μm to make a test solution. Glycerin is prepared to 5 mg / ml, 10 mg / ml, and 15 mg / ml with pure water to obtain a standard solution.
次に、検液および標準溶液20μlにつき、液体クロマトグラフィーを行い、検液の食物繊維画分および標準溶液のグリセリンのピーク面積値を測定する。 Next, liquid chromatography is performed on 20 μl of the test solution and standard solution, and the peak area values of the dietary fiber fraction of the test solution and glycerin of the standard solution are measured.
液体クロマトグラフィーの分析条件は以下の通りである。
検出器:示差屈折計
カラム:ULTRON PS-80N(φ8.0×300 mm、島津ジーエルシー)
カラム温度:50℃
移動相:超純水
流速:0.5ml/min
The analysis conditions for liquid chromatography are as follows.
Detector: Differential refractometer Column: ULTRON PS-80N (φ8.0 × 300 mm, Shimadzu GL)
Column temperature: 50 ° C
Mobile phase: Ultrapure water Flow rate: 0.5 ml / min
食物繊維量は、標準溶液濃度および面積より検量線を作成し、その検量線からグリセロール当量を求め、以下の式から算出する。
食物繊維量(%)=[グリセロール当量(mg/ml)/試料採取量(mg)]×f1×50(ml)×100
(上記式中、f1はグリセリンとブドウ糖のピーク面積の感度比(0.82)である。)
The amount of dietary fiber is calculated from the following equation by preparing a calibration curve from the standard solution concentration and area, obtaining the glycerol equivalent from the calibration curve.
Amount of dietary fiber (%) = [glycerol equivalent (mg / ml) / sampled amount (mg)] × f1 × 50 (ml) × 100
(In the above formula, f1 is the sensitivity ratio (0.82) of the peak area of glycerin and glucose.)
本発明において、ポリデキストロース源として、ポリデキストロースと、その原料となる重合性単量体の1種又は2種以上とを含む混合物であって、25℃における特定濃度の水溶液の粘度が特定値以上である該混合物を用いると、本発明の組成物により胆汁酸ミセルの粒径低下を一層効果的に抑制できることを本発明者らは発見した。具体的には、ポリデキストロース混合物は、この温度における50質量/体積%水溶液の粘度が、15mPa・s以上であることが好ましい。
また、ポリデキストロース混合物における50質量/体積%水溶液の粘度は、高ければ高いほど良いが、25mPa・s以下であるとポリデキストロース混合物の製造コスト等の面からは好ましい。
ここで、ポリデキストロース混合物の水溶液の濃度が「X質量/体積%」であるとは、該水溶液100ml中に含まれているポリデキストロース混合物の質量がXgであることを意味する。
In the present invention, as a polydextrose source, a mixture containing polydextrose and one or more polymerizable monomers as raw materials thereof, and the viscosity of an aqueous solution having a specific concentration at 25 ° C. is a specific value or more The present inventors have found that the use of the mixture as described above enables the composition of the present invention to more effectively suppress the particle size reduction of bile acid micelles. Specifically, the polydextrose mixture preferably has a 50 mass / volume% aqueous solution viscosity of 15 mPa · s or higher at this temperature.
Further, the viscosity of the 50 mass / volume% aqueous solution in the polydextrose mixture is preferably as high as possible, but is preferably 25 mPa · s or less from the viewpoint of the production cost of the polydextrose mixture.
Here, the concentration of the aqueous solution of the polydextrose mixture being “X mass / volume%” means that the mass of the polydextrose mixture contained in 100 ml of the aqueous solution is Xg.
前記の水溶液の粘度は、LVT RVT HAT HBTアナロク粘度計(ブルックフィールド社製)を用い、具体的には、以下の手順により、測定できる。
一例としては、No.1のスピンドルを本体に設置し、調製した80 mLの50質量/体積%のサンプルにスピンドルを一定の位置まで浸す。回転スピードを50rpmに設定し、指針が目盛の0mPa・sを指していることを確認し、モータースイッチを入れる。スピンドル回転開始から1分後の指針の指す数値から粘度を算出して記録する。
The viscosity of the aqueous solution can be measured using an LVT RVT HAT HBT analog viscometer (manufactured by Brookfield) and specifically by the following procedure.
As an example, a No. 1 spindle is placed on the main body, and the spindle is immersed in a prepared position in 80 mL of a 50% mass / volume sample prepared. Set the rotation speed to 50 rpm, check that the pointer points to 0 mPa · s on the scale, and turn on the motor switch. Viscosity is calculated from the numerical value indicated by the pointer 1 minute after the start of spindle rotation and recorded.
前記の水溶液の粘度が前記特定範囲であるポリデキストロース混合物を得るためには、用いるポリデキストロースの分子量や重合度を分画や重合の条件により調整したり、既知の方法により精製したりすればよい。 In order to obtain a polydextrose mixture in which the viscosity of the aqueous solution is in the specific range, the molecular weight and degree of polymerization of the polydextrose used may be adjusted according to fractionation and polymerization conditions, or may be purified by a known method. .
更に、本発明の組成物は、固形物であって、20質量/体積%濃度の水溶液としたときの25℃のpHが特定範囲であることが、本発明の組成物により胆汁酸ミセルの粒径低下を効果的に抑制できるため好ましい。具体的には、本発明の組成物は、20質量/体積%濃度の水溶液としたときに、上記温度におけるpHが2.0より高く、8.0より低いことが好ましく、2.1以上7.9以下であることがより好ましく、2.5以上7.5以下であることが更に好ましく、3.0以上7.0以下であることが最も好ましい。このようなポリデキストロース混合物は、例えば、上述のグルコース及びソルビトールの重合物を既知の方法で精製すること等によって得ることができる。
また、本発明では、ポリデキストロース源として、20質量/体積%水溶液としたときの25℃におけるpHが前記範囲であるポリデキストロース混合物を用いることも好ましい。
更に、本発明の組成物が、25℃におけるpHを前記の範囲に調整した、液状の組成物であることも胆汁酸ミセルの粒径低下を効果的に抑制できる観点から好ましい。本発明の組成物が液状である場合のpHを前記の範囲に調整するためには、ポリデキストロース又はポリデキストロース混合物として、水に溶解乃至分散させたときのpHが前記範囲であるものを用いたり、pH調整剤などを添加すればよい。ここでいう液状の組成物とは、水にポリデキストロース又はポリデキストロース混合物を溶解乃至分散させたものであることが好ましい。液状の組成物は必要に応じてその他の任意成分を含有する。
本発明の組成物及びポリデキストロース混合物の水溶液のpH並びに液状の組成物のpHは、後述の実施例に記載の方法により測定できる。
Further, the composition of the present invention is a solid substance, and the pH of 25 ° C. when it is an aqueous solution having a concentration of 20% by mass / volume is within a specific range, the composition of the present invention enables the bile acid micelle particles It is preferable because a decrease in diameter can be effectively suppressed. Specifically, when the composition of the present invention is an aqueous solution having a concentration of 20% by mass / volume, the pH at the above temperature is preferably higher than 2.0 and lower than 8.0, and preferably 2.1 or more and 7 It is more preferably 0.9 or less, further preferably 2.5 or more and 7.5 or less, and most preferably 3.0 or more and 7.0 or less. Such a polydextrose mixture can be obtained, for example, by purifying the above-mentioned polymer of glucose and sorbitol by a known method.
Moreover, in this invention, it is also preferable to use the polydextrose mixture whose pH in 25 degreeC when it is set as 20 mass / volume% aqueous solution is the said range as a polydextrose source.
Furthermore, it is also preferable that the composition of the present invention is a liquid composition in which the pH at 25 ° C. is adjusted to the above range from the viewpoint of effectively suppressing the decrease in the particle size of bile acid micelles. In order to adjust the pH when the composition of the present invention is liquid to the above range, a polydextrose or polydextrose mixture having a pH in the above range when dissolved or dispersed in water can be used. , PH adjusting agent and the like may be added. The liquid composition here is preferably one obtained by dissolving or dispersing polydextrose or a polydextrose mixture in water. The liquid composition contains other optional components as required.
The pH of the aqueous solution of the composition of the present invention and the polydextrose mixture and the pH of the liquid composition can be measured by the methods described in Examples below.
なお、ポリデキストロースとしては、上記の方法で製造されたポリデキストロースに加えて、該ポリデキストロースの誘導体も含めることができる。そのような誘導体としては、上記の方法で製造されたポリデキストロースを水素添加して得られる水素添加又は還元ポリデキストロースを挙げることができる。また、上記の方法で製造されたポリデキストロースを水酸化カリウム等の塩基で中和したものもポリデキストロースに含まれる。 In addition to polydextrose produced by the above method, polydextrose may also include derivatives of the polydextrose. Examples of such derivatives include hydrogenated or reduced polydextrose obtained by hydrogenating polydextrose produced by the above method. Further, polydextrose produced by neutralizing the polydextrose produced by the above method with a base such as potassium hydroxide is also included in polydextrose.
本発明の組成物は経口摂取することが可能であり、その場合、該組成物の剤形としては、例えば、粉末状、粒状、顆粒状、錠状、棒状、板状、ブロック状、固形状、丸状、液状、飴状、ペースト状、クリーム状、ハードカプセルやソフトカプセルのようなカプセル状、カプレット状、タブレット状、ゲル状、ゼリー状、グミ状、ウエハース状、ビスケット状、クッキー状、チュアブル状、シロップ状、スティック状等の各形態が挙げられる。 The composition of the present invention can be taken orally. In this case, the dosage form of the composition is, for example, powder, granule, granule, tablet, rod, plate, block, solid , Round, liquid, candy, paste, cream, capsule like hard capsule or soft capsule, caplet, tablet, gel, jelly, gummy, wafer, biscuit, cookie, chewable , Syrup form, stick form and the like.
本発明の組成物は、ポリデキストロース又はポリデキストロース混合物のみからなるものであってもよいし、これらに加えてその他の成分を含有していてもよい。その他の成分としては、例えば、ビタミン類、タンパク質、ポリデキストロース以外の水溶性食物繊維、オリゴ糖、ミネラル類、ムコ多糖類、乳製品、豆乳製品、植物又は植物加工品、乳酸菌、納豆菌、酪酸菌、麹菌、酵母などの微生物を配合することができる。更に必要に応じて通常食品分野で用いられる、糖類、甘味料、酸味料、着色料、増粘剤、光沢剤、製造用剤、酸化防止剤、pH調整剤等を挙げることができる。その他の成分としては、これら以外にも、種々の賦形剤、結合剤、滑沢剤、安定剤、希釈剤、増量剤、増粘剤、乳化剤、着色料、香料、食品添加物、調味料などを挙げることができる。その他の成分の含有量は、本発明の組成物の形態等に応じて適宜選択することができる。 The composition of the present invention may be composed only of polydextrose or polydextrose mixture, and may contain other components in addition to these. Other ingredients include, for example, vitamins, proteins, water-soluble dietary fibers other than polydextrose, oligosaccharides, minerals, mucopolysaccharides, dairy products, soy milk products, plants or processed plant products, lactic acid bacteria, natto bacteria, butyric acid Microorganisms such as fungi, bacilli and yeast can be blended. Furthermore, sugars, sweeteners, acidulants, colorants, thickeners, brighteners, production agents, antioxidants, pH adjusters and the like that are usually used in the food field as needed can be mentioned. Other ingredients include various excipients, binders, lubricants, stabilizers, diluents, extenders, thickeners, emulsifiers, colorants, flavors, food additives, seasonings. And so on. The content of other components can be appropriately selected according to the form of the composition of the present invention.
本発明の組成物におけるポリデキストロースの含有量は該組成物の用途や剤形、求められる効果のレベル等によっても異なるが、一般に、本発明の組成物の固形分中、ポリデキストロースの割合が3.0質量%以上100質量%以下であることが好ましく、3.3質量%以上100質量%以下であることがより好ましい。 The content of polydextrose in the composition of the present invention varies depending on the use and dosage form of the composition, the required level of effect, etc., but generally the proportion of polydextrose in the solid content of the composition of the present invention is 3.0. The mass is preferably from 100% by mass to 100% by mass, and more preferably from 3.3% by mass to 100% by mass.
また、本発明の組成物が液体にポリデキストロースを溶解したものである場合、該組成物中のポリデキストロースの濃度は、10g/L以上900g/L以下であることが好ましく、10g/L以上800g/L以下であることが更に好ましい。 When the composition of the present invention is a solution in which polydextrose is dissolved in a liquid, the concentration of polydextrose in the composition is preferably 10 g / L or more and 900 g / L or less, preferably 10 g / L or more and 800 g. / L or less is more preferable.
また、本発明の組成物が、水等の液体にポリデキストロース混合物を溶解したものである場合、該組成物中のポリデキストロース混合物の濃度は、0.1質量/体積%以上50質量/体積%以下であることが好ましく、0.5質量/体積%以上40質量/体積%以下であることがより好ましく、1質量/体積%以上30質量/体積%以下であることが更に好ましくい。 Further, when the composition of the present invention is obtained by dissolving a polydextrose mixture in a liquid such as water, the concentration of the polydextrose mixture in the composition is 0.1 mass / volume% or more and 50 mass / volume%. Is preferably 0.5 mass / volume% or more and 40 mass / volume% or less, more preferably 1 mass / volume% or more and 30 mass / volume% or less.
また、本発明の組成物におけるポリデキストロースの摂取量としては、ポリデキストロースの量として、1食あたり、1g以上30g以下であることが好ましく、2g以上20g以下であることが更に好ましく、3g以上12g以下であることがより好ましい。 The amount of polydextrose in the composition of the present invention is preferably 1 g or more and 30 g or less, more preferably 2 g or more and 20 g or less, and more preferably 3 g or more and 12 g or less as polydextrose. It is more preferable that
本発明の組成物は、経口摂取した場合、消化管内において胆汁酸ミセルの粒径低下を抑制することができる。 When the composition of the present invention is orally ingested, the particle size reduction of bile acid micelles can be suppressed in the digestive tract.
胆汁酸ミセルとは、具体的には、胆汁酸存在下で脂肪の分解物が形成するミセルをいう。胆汁酸とは、哺乳類の胆汁中に広く見出されるステロイド誘導体でコラン酸骨格を有する化合物の総称である。胆汁酸の例としては、COOH型の胆汁酸、抱合胆汁酸、及びそれらの塩等が挙げられる。COOH型の胆汁酸の例としては、コール酸、ケノデオキシコール酸、ヒオコール酸、5α-シプリノール、デオキシコール酸、リトコール酸、ウルソデオキシコール酸、ヒオデオキシコール酸等が挙げられる。また抱合胆汁酸の例としては、COOH型の胆汁酸のカルボキシル基がタウリンやグリシンとアミド結合したものが挙げられ、例えば、グリココール酸、タウロコール酸等が挙げられる。また、上述したCOOH型の胆汁酸及び抱合胆汁酸の塩としては、ナトリウム塩、カリウム塩等が挙げられる。本発明において、胆汁酸は、抱合胆汁酸又はその塩を含むことが好ましい。また、胆汁酸ミセルは、脂肪酸及びモノグリセリドを含むことが好ましく、脂肪酸及び2−モノグリセリドを含むことが特に好ましい。前記の脂肪酸は、飽和脂肪酸であっても不飽和脂肪酸でもあってもよい。 The bile acid micelle specifically refers to a micelle formed by a decomposition product of fat in the presence of bile acid. Bile acid is a generic name for compounds having a colanic acid skeleton, which are steroid derivatives widely found in mammalian bile. Examples of bile acids include COOH-type bile acids, conjugated bile acids, and salts thereof. Examples of the COOH-type bile acids include cholic acid, chenodeoxycholic acid, hyocholic acid, 5α-cypurinol, deoxycholic acid, lithocholic acid, ursodeoxycholic acid, hyodeoxycholic acid and the like. Examples of conjugated bile acids include those in which the carboxyl group of COOH-type bile acids is amide-bonded with taurine or glycine, and examples include glycocholic acid and taurocholic acid. Examples of the COOH-type bile acid and conjugated bile acid salts described above include sodium salts and potassium salts. In the present invention, the bile acid preferably contains a conjugated bile acid or a salt thereof. Moreover, it is preferable that a bile acid micelle contains a fatty acid and a monoglyceride, and it is especially preferable that a fatty acid and 2-monoglyceride are included. The fatty acid may be a saturated fatty acid or an unsaturated fatty acid.
このような本発明の組成物は、消化管内の胆汁酸ミセルの粒径低下を抑制することにより、小腸上皮における脂肪酸やモノグリセリドの吸収を遅延させ、有効に抑制し得る。また、消化管内の胆汁酸ミセルの粒径低下を抑制することにより、脂質の体外への排出を促進し得る。したがって、本発明の組成物は中性脂肪の吸収を抑制する用途に有効である。 Such a composition of the present invention can effectively suppress the absorption of fatty acids and monoglycerides in the small intestinal epithelium by suppressing the decrease in the particle size of bile acid micelles in the digestive tract. Moreover, the discharge | emission of a lipid outside a body can be accelerated | stimulated by suppressing the particle size fall of the bile acid micelle in a digestive tract. Therefore, the composition of this invention is effective for the use which suppresses absorption of a neutral fat.
以下、実施例を挙げて本発明を更に詳細に説明する。しかし本発明の範囲はかかる実施例に限定されない。以下、特に断らない場合「%」は質量%、「部」は質量部を表す。
尚、以下の食物繊維量及び粘度は上述した方法で測定した。
Hereinafter, the present invention will be described in more detail with reference to examples. However, the scope of the present invention is not limited to such examples. Hereinafter, unless otherwise specified, “%” represents mass%, and “part” represents mass part.
In addition, the following dietary fiber amount and viscosity were measured by the method mentioned above.
〔実施例1〕
ポリデキストロースとして、以下のポリデキストロース混合物Aを蒸留水に溶解し、20質量/体積%の水溶液サンプルとした。
ポリデキストロース混合物A:
50質量/体積%水溶液の25℃での粘度が20mPa・s、食物繊維量が80.16質量%、(A)食物繊維量と、(B)グルコース及びソルビトールの合計量の比(A)/(B)が18.6。
[Example 1]
As polydextrose, the following polydextrose mixture A was dissolved in distilled water to obtain a 20 mass / volume% aqueous solution sample.
Polydextrose mixture A:
Viscosity of 50 mass / volume% aqueous solution at 25 ° C. is 20 mPa · s, dietary fiber content is 80.16 mass%, ratio of (A) dietary fiber content and (B) total amount of glucose and sorbitol (A) / (B) is 18.6.
〔比較例1〕
ポリデキストロース混合物の水溶液の代わりに、難消化性デキストリン含有物(難消化性デキストリン量が94.4質量%)を蒸留水に溶解し、20質量/体積%の水溶液サンプルとした。
[Comparative Example 1]
Instead of the aqueous solution of the polydextrose mixture, an indigestible dextrin-containing material (the amount of indigestible dextrin was 94.4% by mass) was dissolved in distilled water to obtain a 20% by mass / aqueous solution sample.
前記で得られた実施例1及び比較例1の水溶液サンプルを、以下の<ミセル形成試験>に供した。また、水溶液サンプルの代わりに蒸留水を用い、参考例1(陰性コントロール)として、同様の<ミセル形成試験>を行った。 The aqueous solution samples of Example 1 and Comparative Example 1 obtained above were subjected to the following <micelle formation test>. Further, distilled water was used instead of the aqueous solution sample, and a similar <micelle formation test> was performed as Reference Example 1 (negative control).
<ミセル形成試験>
タウロコール酸ナトリウム0.0125g及び2−モノオレイン0.0195gを1.5mLエッペンチューブに量り入れた。
この1.5mLエッペンチューブに、前記の水溶液サンプル(実施例1若しくは比較例1)又は蒸留水(参考例1)を500μL、及び、オレイン酸34.25μLを加え、ボルテックスで10秒撹拌した。得られた混合物を室温下、ホモジナイザー(マイクロテック・ニチオン社製、ヒストコロンNS−310EII)で3分間、均一化した。ここでホモジナイザーの強度は4に設定した。均一化処理の30秒後、エッペンチューブの底から2μLサンプリングし、あらかじめ(1時間以上)37℃に加温しておいた1mLの0.15%SDS溶液に加えて希釈した。希釈後、この希釈液のミセルの平均直径を、Malvern社製「ゼータサイザーNano s」を用いて測定し、「均一化処理0分後の平均直径」とした。測定温度は37℃とした。前記の均一化処理の60、120、180分後においても、前記で均一化した液からそれぞれ同様のサンプリング及び希釈を行い、ミセルの平均直径を測定し、それぞれ「均一化後60、120、180分後の平均直径」とした。均一化した液及びその希釈液は、いずれも180分後の測定が終了するまで37℃で静置させた。均一化後60、120、180分後の平均直径の平均値それぞれについて、均一化後0分後の平均直径の平均値を100としたときの割合を算出した。その結果を図1に示す。
<Micelle formation test>
0.0125 g of sodium taurocholate and 0.0195 g of 2-monoolein were weighed into a 1.5 mL Eppendorf tube.
500 μL of the aqueous solution sample (Example 1 or Comparative Example 1) or distilled water (Reference Example 1) and 34.25 μL of oleic acid were added to the 1.5 mL Eppendorf tube, and the mixture was stirred by vortexing for 10 seconds. The obtained mixture was homogenized at room temperature for 3 minutes with a homogenizer (manufactured by Microtech Nichion Co., Ltd., Histocolon NS-310EII). Here, the strength of the homogenizer was set to 4. After 30 seconds of the homogenization treatment, 2 μL was sampled from the bottom of the Eppendorf tube, and diluted by adding to 1 mL of 0.15% SDS solution that had been heated to 37 ° C. (1 hour or more) in advance. After dilution, the average micelle diameter of the diluted solution was measured using “Zeta Sizer Nano s” manufactured by Malvern, and defined as “average diameter after 0 minutes of homogenization treatment”. The measurement temperature was 37 ° C. Even after 60, 120, 180 minutes of the homogenization treatment, the same sampling and dilution were performed from the homogenized liquid, and the average micelle diameter was measured. The average diameter after minutes ”. Both the homogenized liquid and the diluted liquid were allowed to stand at 37 ° C. until the measurement after 180 minutes was completed. For each average value of the average diameter after 60, 120, and 180 minutes after homogenization, the ratio when the average value of the average diameter after 0 minutes after homogenization was 100 was calculated. The result is shown in FIG.
図1に示すように、ポリデキストロースを用いた実施例1においては、難消化性デキストリンを用いた比較例1及び陰性コントロールである参考例1に比べて、胆汁酸ミセルの平均粒子径の低下が抑制された。したがって、ポリデキストロースを用いた本発明の組成物が、胆汁酸ミセルの粒径低下を効果的に抑制することが判る。 As shown in FIG. 1, in Example 1 using polydextrose, the average particle size of bile acid micelles was decreased compared to Comparative Example 1 using indigestible dextrin and Reference Example 1 being a negative control. Suppressed. Therefore, it can be seen that the composition of the present invention using polydextrose effectively suppresses the particle size reduction of bile acid micelles.
〔実施例2〜4〕
実施例1で用いたポリデキストロース混合物Aと製造条件が異なるポリデキストロース混合物3種を製造した。これらポリデキストロース混合物について上記の方法で測定した食物繊維量は表1の通りである。得られたポリデキストロース混合物を蒸留水に溶解し、20質量/体積%の水溶液サンプルとした。
[Examples 2 to 4]
Three types of polydextrose mixtures having different production conditions from the polydextrose mixture A used in Example 1 were produced. Table 1 shows the dietary fiber content of these polydextrose mixtures measured by the above method. The obtained polydextrose mixture was dissolved in distilled water to obtain a 20 mass / volume% aqueous solution sample.
実施例2〜4のサンプルを上記の<ミセル形成試験>に供した結果を、図2に示す。図2には、図1と同様に、蒸留水を陰性コントロールとして用いた結果を参考例2として併せて示している。 The result of having used the sample of Examples 2-4 for said <micelle formation test> is shown in FIG. In FIG. 2, the result of using distilled water as a negative control is also shown as Reference Example 2 as in FIG.
〔実施例5〜8〕
実施例1で用いたポリデキストロース混合物と製造条件が異なるポリデキストロース混合物を4種製造した。これらポリデキストロース混合物について50質量/体積%の水溶液の粘度(mPa・s)を上記の方法で測定した。その結果は表2の通りである。表2における参考例3は、蒸留水である。
[Examples 5 to 8]
Four polydextrose mixtures having different production conditions from the polydextrose mixture used in Example 1 were produced. With respect to these polydextrose mixtures, the viscosity (mPa · s) of 50 mass / volume% aqueous solution was measured by the above method. The results are shown in Table 2. Reference Example 3 in Table 2 is distilled water.
実施例5〜8で用いた各ポリデキストロース混合物を、20質量/体積%の水溶液サンプルとし、これらを上記の<ミセル形成試験>に供した。実施例5〜8で用いた各ポリデキストロース混合物について、50質量/体積%の水溶液の粘度(mPa・s)を横軸に、20質量/体積%の水溶液サンプルを<ミセル形成試験>に供して得られた平均粒径(均一化後0分後の平均粒径を100とした時の均一化後180分後の平均粒径の割合、%)を縦軸にプロットしたグラフを図3に示す。図3には、陰性コントロールとして用いた蒸留水(参考例3)の粘度及び該蒸留水を<ミセル形成試験>に供して得られた平均粒径も併せて示している。 Each polydextrose mixture used in Examples 5 to 8 was used as a 20 mass / volume% aqueous solution sample, and these were subjected to the above-described <micelle formation test>. About each polydextrose mixture used in Examples 5-8, the viscosity (mPa * s) of 50 mass / volume% aqueous solution was used for the horizontal axis, and the 20 mass / volume% aqueous solution sample was used for <micelle formation test>. FIG. 3 is a graph in which the obtained average particle diameter (ratio of average particle diameter after 180 minutes after homogenization,% when the average particle diameter after 0 minutes after homogenization is 100) is plotted on the vertical axis. . FIG. 3 also shows the viscosity of distilled water used as a negative control (Reference Example 3) and the average particle diameter obtained by subjecting the distilled water to the <micelle formation test>.
図2に示す結果から、食物繊維量が50質量%以上であるポリデキストロース混合物を用いると、胆汁酸ミセルの粒径の低下がより一層効果的に抑制されることが判る。また、図3に示す結果から、50質量/体積%の水溶液の粘度が15mPa・s以上であるポリデキストロース混合物を用いても、胆汁酸ミセルの粒径の低下がより一層効果的に抑制されることが判る。 From the results shown in FIG. 2, it can be seen that when a polydextrose mixture having a dietary fiber content of 50% by mass or more is used, a decrease in the particle size of bile acid micelles is more effectively suppressed. Further, from the results shown in FIG. 3, even when a polydextrose mixture having a viscosity of an aqueous solution of 50% by mass / volume of 15 mPa · s or more is used, the decrease in the particle size of bile acid micelles is further effectively suppressed. I understand that.
〔実施例9〕
ポリデキストロース混合物(食物繊維量70%)を蒸留水に溶解して、液状の組成物(ポリデキストロース混合物濃度:20質量/体積%)とした。このとき液状の組成物のpHはクエン酸を用いて2.0に調整した。pHは以下方法で測定した。
Example 9
A polydextrose mixture (dietary fiber content 70%) was dissolved in distilled water to obtain a liquid composition (polydextrose mixture concentration: 20 mass / volume%). At this time, the pH of the liquid composition was adjusted to 2.0 using citric acid. The pH was measured by the following method.
<pHの測定方法>
pHメーターとしてメトラートレド社製「セブンイージー」を使用して25℃で測定した。
<Measurement method of pH>
The measurement was performed at 25 ° C. using “Seven Easy” manufactured by METTLER TOLEDO as a pH meter.
〔実施例10〕
pHを3.0に調整した以外は、実施例9と同様にして、液状の組成物(ポリデキストロース混合物濃度:20質量/体積%、pH3.0)を得た。
Example 10
A liquid composition (polydextrose mixture concentration: 20 mass / volume%, pH 3.0) was obtained in the same manner as in Example 9, except that the pH was adjusted to 3.0.
〔実施例11〕
ポリデキストロース混合物(食物繊維量70%)を蒸留水に溶解して、液状の組成物(ポリデキストロース混合物濃度:20質量/体積%)とした。この液状の組成物のpHを、上記のようにして測定したところ、pH5.36であった。
Example 11
A polydextrose mixture (dietary fiber content 70%) was dissolved in distilled water to obtain a liquid composition (polydextrose mixture concentration: 20 mass / volume%). The pH of this liquid composition was measured as described above, and it was pH 5.36.
〔実施例12〕
水酸化ナトリウムを用いてpHを7.0に調整した以外は、実施例9と同様にして、液状の組成物(ポリデキストロース混合物濃度:20質量/体積%、pH7.0)を得た。
Example 12
A liquid composition (polydextrose mixture concentration: 20 mass / volume%, pH 7.0) was obtained in the same manner as in Example 9, except that the pH was adjusted to 7.0 using sodium hydroxide.
〔実施例13〕
水酸化ナトリウムを用いてpHを8.0に調整した以外は、実施例10と同様にして、液状の組成物(ポリデキストロース混合物濃度:20質量/体積%、pH8.0)を得た。
Example 13
A liquid composition (polydextrose mixture concentration: 20 mass / volume%, pH 8.0) was obtained in the same manner as in Example 10 except that the pH was adjusted to 8.0 using sodium hydroxide.
実施例9〜13で得られた液状の組成物それぞれを水溶液サンプルとして、上記の<ミセル形成試験>に供して平均粒径(均一化後0分後の平均粒径を100とした時の均一化後180分後の平均粒径の割合、%)を得た。液状の組成物のpHを横軸とし、縦軸を、当該平均粒径としてプロットしたグラフを図4に示す。 Each of the liquid compositions obtained in Examples 9 to 13 was used as an aqueous solution sample and subjected to the above-described <micelle formation test> to obtain an average particle size (uniform when the average particle size 0 minutes after homogenization was 100) The ratio of the average particle diameter 180% after the conversion was obtained. FIG. 4 is a graph in which the pH of the liquid composition is plotted on the horizontal axis and the vertical axis is plotted on the average particle diameter.
図4に示す結果から、ポリデキストロース混合物及び固形状の組成物として、20質量/体積%濃度の水溶液のpHが2.0超8.0未満のものを用いると、胆汁酸ミセルの粒径の低下が効果的に抑制されることが判る。また、pHが2.0超8.0未満である実施例10、11及び12の液状の組成物を用いると、pHが2.0以下の実施例9及びpHが8.0以上の実施例13の組成物に比べて、胆汁酸ミセルの粒径の低下がより一層効果的に抑制されることが判る。 From the results shown in FIG. 4, when a polydextrose mixture and a solid composition having a 20 mass / volume% aqueous solution with a pH of more than 2.0 and less than 8.0 are used, the particle size of bile acid micelles It can be seen that the reduction is effectively suppressed. Further, when the liquid compositions of Examples 10, 11 and 12 having a pH of more than 2.0 and less than 8.0 were used, Example 9 having a pH of 2.0 or less and Example having a pH of 8.0 or more It can be seen that the decrease in the particle size of the bile acid micelles is more effectively suppressed as compared to the composition of 13.
(配合例1:散剤)
ポリデキストロース(食物繊維量80%)に対して製造上必要な賦形剤を添加して、ポリデキストロースが95%となる散剤の態様で本発明の組成物を調製した。
(Formulation Example 1: Powder)
Excipients necessary for production were added to polydextrose (80% dietary fiber content) to prepare a composition of the present invention in the form of a powder in which polydextrose was 95%.
(配合例2:錠剤)
全体を100部として、ポリデキストロース(食物繊維量50%)5部、ビタミンB1 5部、ビタミンB6 12部、ステアリン酸カルシウム 4部、麦芽糖30部及びヒドロキシプロピルセルロース 残部を混合及び打錠することにより、錠剤の態様で本発明の組成物を調製した。
(Formulation Example 2: Tablet)
Mix and tablet 5 parts of polydextrose (50% dietary fiber), 5 parts of vitamin B 1 , 12 parts of vitamin B 6 , 4 parts of calcium stearate, 30 parts of maltose and the rest of hydroxypropylcellulose The composition of the present invention was prepared in the form of a tablet.
(配合例3:顆粒剤)
全体を100部として、ポリデキストロース(食物繊維量 70%) 90部、茶抽出物 5部、香料 若干量、ステアリン酸カルシウム 残部を混合及び顆粒化することにより、顆粒剤の態様で本発明の組成物を調製した。
(Formulation Example 3: Granules)
The composition of the present invention in the form of granules by mixing and granulating 90 parts of polydextrose (dietary fiber content 70%), 5 parts of tea extract, some amount of fragrance, and the remainder of calcium stearate with 100 parts as a whole. Was prepared.
(配合例4:カプセル剤)
全体を100部として、ポリデキストロース(食物繊維量 50%)40部、レシチン 8部及びオリーブ油 残部を混合して調製したものを内容液として、これをカプセル殻に内包することにより、カプセル剤の態様で本発明の組成物を調製した。
(Formulation Example 4: Capsule)
An embodiment of a capsule containing 100 parts as a whole and mixing 40 parts of polydextrose (dietary fiber amount 50%), 8 parts of lecithin and the remainder of olive oil as a content liquid and encapsulating it in a capsule shell The composition of the present invention was prepared.
(配合例5:液剤)
全体を100部として、ポリデキストロース(食物繊維量 75%) 1部、ビタミンB1 1部、果糖ブドウ糖液糖 10部、クエン酸 1部、安息香酸ナトリウム 0.02部、香料製剤 2部、スクラロース 0.05部、アセスルファムカリウム 0.03部、及び精製水 残部を混合して、液剤の態様で本発明の組成物を調製した。
(Formulation Example 5: Liquid formulation)
Total 100 parts, 1 part polydextrose (dietary fiber 75%) 1 part, vitamin B 1 1 part, fructose glucose liquid sugar 10 parts, citric acid 1 part, sodium benzoate 0.02 part, flavor preparation 2 parts, sucralose The composition of the present invention was prepared in the form of a liquid by mixing 0.05 part, 0.03 part acesulfame potassium, and the remaining purified water.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015037298A JP2015199700A (en) | 2014-03-31 | 2015-02-26 | Neutral fat absorption-suppressing composition |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014073871 | 2014-03-31 | ||
JP2014073871 | 2014-03-31 | ||
JP2015037298A JP2015199700A (en) | 2014-03-31 | 2015-02-26 | Neutral fat absorption-suppressing composition |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2015199700A true JP2015199700A (en) | 2015-11-12 |
Family
ID=54551336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015037298A Ceased JP2015199700A (en) | 2014-03-31 | 2015-02-26 | Neutral fat absorption-suppressing composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2015199700A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3876794A (en) * | 1972-12-20 | 1975-04-08 | Pfizer | Dietetic foods |
JP2006519006A (en) * | 2003-02-26 | 2006-08-24 | ダニスコ エイ/エス | Novel use of polydextrose in edible products, edible products containing polydextrose, and methods of including polydextrose in edible products |
JP2012136484A (en) * | 2010-12-27 | 2012-07-19 | Api Co Ltd | Intestinal harmful substance adsorbent, and method for producing the same |
-
2015
- 2015-02-26 JP JP2015037298A patent/JP2015199700A/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3876794A (en) * | 1972-12-20 | 1975-04-08 | Pfizer | Dietetic foods |
JP2006519006A (en) * | 2003-02-26 | 2006-08-24 | ダニスコ エイ/エス | Novel use of polydextrose in edible products, edible products containing polydextrose, and methods of including polydextrose in edible products |
JP2012136484A (en) * | 2010-12-27 | 2012-07-19 | Api Co Ltd | Intestinal harmful substance adsorbent, and method for producing the same |
Non-Patent Citations (8)
Title |
---|
ACTA NUTRIMENTA SINICA, vol. 13, no. 2, JPN6017013716, June 1991 (1991-06-01), pages 171 - 173, ISSN: 0003541152 * |
JOURNAL OF HEALTH SCIENCE, vol. 55, no. 5, JPN6017045905, 2009, pages 838 - 844, ISSN: 0003692700 * |
PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 215, no. 1, JPN6017013717, May 1997 (1997-05-01), pages 53 - 58, ISSN: 0003541155 * |
改訂 医薬品添加物ハンドブック, vol. 第1刷, JPN6016050828, 28 February 2007 (2007-02-28), pages 883 - 886, ISSN: 0003473523 * |
日本栄養・食糧学会総会講演要旨集, JPN6016050826, 1 April 2005 (2005-04-01), pages 59 - 2, ISSN: 0003473522 * |
日本臨床栄養学会雑誌, vol. 11, no. 1, JPN6017013711, 10 September 1989 (1989-09-10), pages 51 - 46, ISSN: 0003541151 * |
繊維と工業, vol. 48, no. 4, JPN6017013714, 1992, pages 40 - 45, ISSN: 0003541154 * |
肥満研究, vol. 3, no. 2, JPN6017013713, 1997, pages 30 - 33, ISSN: 0003541153 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0942714B1 (en) | A product, a method for its production, and its use | |
EP1843668B1 (en) | Powder compositions | |
CN1414834A (en) | Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein | |
ES2980700T3 (en) | Dispersion of phytosterols | |
JPWO2006106926A1 (en) | Oil-in-water emulsion containing lignan compounds and composition containing the same | |
WO2009021860A1 (en) | Hoodia extract oil compositions comprising medium chain triglycerides | |
JP2008536879A (en) | Drug or nutrition combination preparation and preparation, method for improving absorption by internal use, and application method thereof | |
CN107530358B (en) | Gel capsules containing sterols and solubilizers | |
US20020183298A1 (en) | Pharmaceutical and food compositions containing" wood alcohols" or" wood sterols" useful for lowering serum cholesterol | |
JP3870740B2 (en) | Ceramide dispersion, production method and application | |
JP4644135B2 (en) | Coenzyme Q10-containing composition | |
JP2013245213A (en) | Clathrate of eriobotrya japonica leaf culture extract and cyclodextrin | |
JP2010511392A (en) | Method for producing a sterol formulation | |
JP2013078307A (en) | Beverage composition | |
JP2015199700A (en) | Neutral fat absorption-suppressing composition | |
CN105213309A (en) | A kind of have Semen Coicis oil Orally taken emulsion increasing immunity and preparation method thereof | |
JP2007124917A (en) | Method for producing rice oil richly containing oryzanol, and usage of the rice oil | |
EP2278890A1 (en) | Compositions of phytosterols with enhanced bioavailability | |
US11844762B2 (en) | Fat absorption inhibiting agent, food and defatted sesame seeds, and method for inhibiting obesity | |
EP2744355B1 (en) | Edible composition comprising sterol | |
KR20210025033A (en) | A composition having improved bioavailability of isoflavone | |
EP2052727A2 (en) | Hoodia extract oil compositions comprising unsaturated monoacylglycerides | |
JP2002238500A (en) | Tocopherol preparation suppressed in deterioration of flavor and food and drink obtained by formulating the same | |
US20060204630A1 (en) | Compositions of sugar-containing sterol solids dispersions | |
JP2005269941A (en) | Phytosterol composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20160302 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160331 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170309 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170425 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170619 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170914 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20171205 |
|
AA92 | Notification that decision to refuse application was cancelled |
Free format text: JAPANESE INTERMEDIATE CODE: A971092 Effective date: 20180109 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180122 |